The Study Of Pathological Features And Prognosis Of Med19Expression In The Prostate Cancer

Objective Med19is a new gene to prostate cancer. The expression of Med19in prostatecancer(Pca), Adjacent tissues of cancer (AT) and benign prostate hyperplasia (BPH) wasexamined with immunohistochemistry. The study analyses that the expression of Med19isconnected with the data of clinical pathology, and discuss the significance of Med19incarcinogenesis, progression, diagnosis and prognosis.Methods The expression of Med19in prostate cancer(Pca), Adjacent tissues of cancer(AT) and benign prostate hyperplasia (BPH) were detected with immunohistochemistry(Sterptavidin peroxidase: sp),the expression of Bcl-2in prostate cancer(Pca) were detectedwith immunohistochemistry (Sterptavidin peroxidase: sp),and all cases were fromChangzheng Hospital, Second Military Medical University from January2006toDecember2010. Among the60cases, there were50cases for prostate cancer(Pca),50cases for Adjacent tissues of cancer (AT) and10cases for benign prostate hyperplasia(BPH), which were used as experiment group, self-control and normal controls, and therelationship and clinical significance of them was investigated conneting with theclinicopathological characteristics and prognosis.Results: The positive expression rate of Med19was52%,10%and8%in prostate cancertissues, the adjacent normal tissue and benign prostatic hyperplasia tissue, respectively,which showed a decreasing trend. The differences between them were statisticallysignificant (Ρ <0.0001). The positive expression rate of Bcl-2was72%in prostate cancer,The expression of Med19was positively correlated with Bcl-2in prostate cancer tissue (Ρ=0.031<0.05). The expression of Med19was correlated with clinicopathological stage,grade and preoperative PSA in prostate cancer tissue and there was a increasing tend, The expression of Med19levels in pT3(84.6%) was higher than in pT2(40.5%) in prostatecancer, and the differences between them were statistically significant (Ρ=0.006).Theexpression in Gleason>7group was higher than those Gleason,=7and Gleason <7groups, the difference was significant (Ρ=0.004), the expression rate also showed anincreasing trend in the PSA <10,10≤PSA <20, the PSA>20prostate cancer groups, butthe difference was not statistically significant (Ρ=0.082). Survival prognosis analysisshowed that PSA-free survival rate in the negative expression of Med19groups wassignificantly lower than the positive expression cases (Ρ=0.029<0.05), however, COXmultivariate regression analysis showed that Gleason score and SM was an onlyindependent prognostic factor for PSA-free survival (Ρ=0.012), the expression of Med19is not an independent prognostic factor for one (Ρ=0.244).Conclusion:(1) The expression Med19in prostate cancer tissues was significantly higherthan their self-control group and normal control group, and it was significantly correlatedwith clinical and pathological stage and histological grade, which suggested that Med19had a significant role in the pathogenesis of prostate cancer.(2) The expression of Med19in prostate cancer was significantly correlated with one ofBcl-2in prostate cancer, which suggested that it may have a synergistic effect in thepathogenesis of prostate cancer, combining the expression of Med19with the expression ofBcl-2to detect may improve the diagnosis of prostate cancer.(3) Univariate survival analysis and COX regression analysis showed Med19may be anindependent prognostic factor of prostate cancer.